Ethan Dmitrovsky, MD, Oral History Interview, March 3, 2015

Ethan Dmitrovsky, MD, Oral History Interview, March 3, 2015

Files

Download Full Interview Transcript (519 KB)

Loading...

Media is loading
 

Description

Major Topics Covered:

  • Personal and educational background; overseas experience and inspiration
  • Research: cell differentiation; retinoids in leukemic differentiation; lung cancer studies
  • The Role of the Provost; personal goals; institutional mandate; detailed of plans
  • MD Anderson’s ten-year strategic plan
  • Research in an environment of changing economics and health care delivery

Identifier

DmitrovskyE_01_20150303

Publication Date

3-5-2015

Publisher

The Historical Resources Center, Research Medical Library, The University of Texas Cancer Center

City

Houston, Texas

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Topics Covered

University of Texas MD Anderson Cancer Center, UT MD Anderson Cancer Center, University of Texas System. M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute at Houston, University of Texas M.D. Anderson Cancer Center, M.D. Anderson Hospital and Tumor Institute

Disciplines

History of Science, Technology, and Medicine | Oncology | Oral History

About the Interview

About the Interview Subject:

Ethan Dmitrovsky, MD came to MD Anderson in 2013 to serve as the institution’s Provost and Executive Vice President. He has a faculty appointment in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Cancer Medicine.

Dr. Dmitrovsky’s translational research areas include: retinoid differentiation-based therapy for acute promyelocytic leukemia (APL); developed the molecular genetic test used to detect the PML/RARalpha transcript from the APL t(15;17) rearrangement; retinoid mechanisms leading to cell cycle arrest and repair of DNA damage in normal/malignant lung epithelial cells; engineered transgenic mouse models that express wild-type or proteasomal degradation-resistant cyclin E species in the lung; derived lung cancer cell lines leading to a new model to assess activity of lung cancer therapy and chemopreventive agents (antineoplastics).

Conditions Governing Access

Open

Ethan Dmitrovsky, MD, Oral History Interview, March 3, 2015

Share

COinS